Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
HBW Insight is a single source of regulatory, legislative, legal and commercial news and insight connecting the dots across 3 sectors, including over the counter medicines, vitamins and dietary supplements, and cosmetics, which have increasing points of intersection, helping you to anticipate global challenges, risks, and opportunities.
How it helps
HBW Insight gives you the power to go behind the news stories to understand the implications of worldwide industry developments across three different but complementary consumer healthcare sectors, on your business.
How it works
A broad network of global expert analysts and journalists give you an insider’s perspective from tracking market events and their impacts from around the globe, to understand the potential impact of developments and trends. Plus, access to exclusive interviews with key opinion leaders and market movers. We also draw on the strength and expertise of the rest of the Pharma Intelligence family of analytical and market intelligence tools.
Health:
In-depth coverage and analysis of:
Beauty:
News and emerging issues in this rapidly evolving global sector on:
Wellness:
Up-to-the-minute news and the informed perspective on:
HBW Insight
By Ryan Nelson 14 Jan 2022
Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.
HBW Insight
By Ryan Nelson 18 Nov 2021
The Environmental Protection Agency does not have the jurisdiction to grant William D. Bush’s request, even if the petitioner had specified the “chemical mixtures” he wants banned or provided the level of data required to initiate proceedings under the Toxic Substances Control Act.
HBW Insight
By Ryan Nelson 17 Aug 2021
The agency’s recent request for contractor quotes cites infants and children, people of color, and immunosuppressed individuals among users whose “unique biological characteristics” could require special consideration in the evaluation of cosmetic ingredients. The FDA also is interested in accounting for unique physicochemical aspects of ingredients such as engineered nanomaterials.
HBW Insight
By Malcolm Spicer 09 Jul 2021
Supplement OWL advisory board members Guru Ramanathan and Russ Michelson answer HBW Insight questions about the site’s progress and the potential for mandatory registration for dietary supplements sold in the US.
HBW Insight
By Eileen Francis 26 May 2021
Senate bill provision allowing FDA to develop unique labeling and packaging for cannabinoid supplements and foods is unnecessary, as the products should following existing labeling regulations, says CRN chief Steve Mister.
HBW Insight
By Tom Gallen 13 May 2021
A year on from the start of the COVID-19 outbreak and a global rush for supplements, Bayer has cemented these sales gains with slight growth at its Nutritionals business in Q1.
HBW Insight
By David Ridley 05 May 2021
As Germany remains in lockdown, sales in its OTC market struggle to return to pre-pandemic levels, according to new data from Sempora Consulting. Meanwhile, COVID-related trends for wellness and online shopping endure, indicating some strategic priorities for OTC firms operating in the country.
HBW Insight
By David Ridley 08 Dec 2020
Europe’s self-care industry has “learned its lessons,” particularly in terms of securing the pharmaceutical ingredient supply chain, and will come out of the coronavirus pandemic stronger, insisted AESGP president Birgit Schuhbauer at the BAH’s High-Level Conference on Future Drug Supply in the European Union.
Topic EU OTC Drugs Coronavirus
HBW Insight
27 Nov 2020
Infographic: COVID-19 delivers an 8% sales growth injection to Germany's supplements market in the first half of the year, accelerating a long-term expansion.
HBW Insight
By Tom Gallen 25 Sep 2020
Nestlé Health Science is expanding its CBD offering outside the US with the UK launch of a dietary supplement formulated by cannabis development firm Geocann.
HBW Insight
By Tom Gallen 15 Jul 2020
Coronavirus pandemic drove up sales of vitamin C supplements and other immunity boosters in Italy in the opening three months of the year.
HBW Insight
By David Ridley 15 Jul 2020
UK's NICE reviews whether Vitamin D can prevent or treat COVID-19, finds evidence wanting.
HBW Insight
By Tom Gallen 15 Jul 2020
Reckitt Benckiser's TV ad for Nurofen in New Zealand drew numerous complaints for being "socially irresponsible" during the COVID-19 pandemic.
HBW Insight
By Eileen Francis 15 Jul 2020
Assertions that no convincing evidence supports that probiotics available in the US treat symptoms of diarrhea, irritable bowel syndrome or allergies look at the category as a whole and not individual strains shown to help with specific conditions, say consumer health industry groups.
Topic Coronavirus Dietary Supplements Research & Development
HBW Insight
By Malcolm Spicer 22 Jun 2020
FDA and FTC continue adding to total each has made during novel coronavirus pandemic. FTC's latest include peroxide gel and licorice as treatments; FDA’s emphasizes in warnings that three businesses' tests were not approved for OTC sales or for home use.
HBW Insight
31 Jan 2023
HBW Insight
31 Jan 2023
HBW Insight
31 Jan 2023
HBW Insight
31 Jan 2023
HBW Insight
30 Jan 2023
HBW Insight
27 Jan 2023
HBW Insight
26 Jan 2023
HBW Insight
26 Jan 2023
HBW Insight
25 Jan 2023
HBW Insight
25 Jan 2023
HBW Insight
25 Jan 2023
HBW Insight
19 Jan 2023
HBW Insight
18 Jan 2023
HBW Insight
17 Jan 2023
HBW Insight
13 Jan 2023
Washington DC
Eileen specializes in
22+ years of experience
Ryan specializes in
18+ years of experience
Washington DC
Malcolm specializes in
16+ years of experience
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
